Theravance Biopharma (TBPH) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Theravance Biopharma, Inc. Reports Second Quarter 2016 Financial Results and Provides Business Update
August 8, 2016 4:15 PM EDTDUBLIN, IRELAND -- (Marketwired) -- 08/08/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the second quarter ended June 30, 2016. Revenue for the second quarter 2016 was $5.5 million. The second quarter operating loss excluding share-based compensation was $37.6 million, or $47.5 million including share-based compensation of $9.9 million. Cash, cash equivalents, and marketable securities totaled $302.0 million as of June 30, 2016. The quarter-end cash balance excludes $35.1 million in receivables from collaborative arrangements. Also excluded from quarter-end cash is a $15.0 million upfront payment expected in the third quarter from Takeda Pharmaceuticals associated with the TD-8954 license... More
